Hongling L. Peng

Renminzhong Road 139
Changsha, 410011, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 106 publications

Current status and progress of staging and efficacy evaluation of marginal zone lymphoma

Current status and progress of staging and efficacy evaluation of marginal zone lymphoma

Journal: Zhonghua yi xue za zhi

Published: June 15, 2026

Combining clinical and pathological features to explore the diagnostic challenges of marginal zone lymphoma

Combining clinical and pathological features to explore the diagnostic challenges of marginal zone lymphoma

Journal: Zhonghua yi xue za zhi

Published: June 15, 2026

Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation.

Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation.

Journal: Blood cancer journal

Published: April 06, 2026

AI-Enhanced Quantitative IHC Analysis for Prognostic Stratification in Marginal Zone Lymphoma: Development of a Revised MZL-IPI Model.

AI-Enhanced Quantitative IHC Analysis for Prognostic Stratification in Marginal Zone Lymphoma: Development of a Revised MZL-IPI Model.

Journal: Diagnostics (Basel, Switzerland)

Published: March 25, 2026

Seven-day Venetoclax Combined With Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia.

Seven-day Venetoclax Combined With Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 06, 2026

Leukocyte Receptor Tyrosine Kinase is A Novel Therapeutic Target In B-Cell Acute Lymphoblastic Leukemia.

Leukocyte Receptor Tyrosine Kinase is A Novel Therapeutic Target In B-Cell Acute Lymphoblastic Leukemia.

Journal: Current cancer drug targets

Published: January 31, 2026

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: December 23, 2025

Risk factors and management strategies in acute promyelocytic leukemia: a real-world single-center retrospective study.

Risk factors and management strategies in acute promyelocytic leukemia: a real-world single-center retrospective study.

Journal: Frontiers in medicine

Published: November 24, 2025

Transformation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia into diffuse large B-cell lymphoma: five cases report and literature review

Transformation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia into diffuse large B-cell lymphoma: five cases report and literature review

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: October 27, 2025

Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma

Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: October 14, 2025

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study.

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study.

Journal: Annals of hematology

Published: September 09, 2025

Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).

Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).

Journal: Journal of the National Cancer Center

Published: September 08, 2025

Showing 1-12 of 106

Last Updated: 09/26/2026